Radius Announces Update on TYMLOS® (abaloparatide) Label

Posted: December 24, 2021 at 1:57 am

BOSTON, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that the U.S. Food and Drug Administration (FDA) has approved updates to the TYMLOS label, including the removal of the boxed warning regarding the risk of osteosarcoma.

Read more here:
Radius Announces Update on TYMLOS® (abaloparatide) Label

Related Posts